AbCellera Biologics Inc. Common Shares (ABCL) is a publicly traded Healthcare sector company. As of May 21, 2026, ABCL trades at $4.54 with a market cap of $1.27B and a P/E ratio of -9.37. ABCL moved +12.72% today. Year to date, ABCL is +33.24%; over the trailing twelve months it is +118.66%. Its 52-week range spans $1.89 to $6.52. Analyst consensus is strong buy with an average price target of $8.75. Rallies surfaces ABCL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies AI research for ABCL combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
| Metric | Value |
|---|---|
| Price | $4.54 |
| Market Cap | $1.27B |
| P/E Ratio | -9.37 |
| EPS | $-0.48 |
| Dividend Yield | 0.00% |
| 52-Week High | $6.52 |
| 52-Week Low | $1.89 |
| Volume | 115.64K |
| Avg Volume | 0 |
| Revenue (TTM) | $79.21M |
| Net Income | $-143.96M |
| Gross Margin | 0.00% |
6 analysts cover ABCL: 0 strong buy, 6 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $8.75.